AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Rolipram has been studied for its potential anti-inflammatory effects due to its ability to inhibit PDE4. By increasing levels of intracellular cAMP, rolipram can modulate immune cell function and reduce the production of pro-inflammatory cytokines and mediators. This property makes it potentially useful for the treatment of inflammatory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD).
Neuroprotective Effects: Rolipram has also been investigated for its potential neuroprotective effects in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and stroke. By inhibiting PDE4 and increasing cAMP levels, rolipram may enhance neuronal survival, promote neurogenesis, and reduce neuroinflammation and oxidative stress. These effects could potentially slow disease progression and improve cognitive function in affected individuals.
Antidepressant Effects: Some research suggests that rolipram may have antidepressant properties due to its ability to increase cAMP levels in the brain. By modulating neurotransmitter signaling pathways involved in mood regulation, such as the serotonin and noradrenaline pathways, rolipram may exert antidepressant effects in animal models of depression. However, clinical studies in humans have been limited, and further research is needed to evaluate the efficacy and safety of rolipram as an antidepressant.
Memory Enhancement: Rolipram has been investigated for its potential to enhance cognitive function and memory in animal models. By increasing cAMP levels and facilitating synaptic plasticity in the brain, rolipram may improve learning and memory processes. These effects could have implications for the treatment of cognitive deficits associated with aging, neurodegenerative diseases, and psychiatric disorders.
Side Effects: While rolipram has shown promise in preclinical studies for various medical conditions, its clinical use has been limited by its potential side effects. Common side effects of rolipram include nausea, vomiting, diarrhea, and headaches. In addition, rolipram has been associated with more serious adverse effects such as cardiac arrhythmias and hepatic toxicity, which have raised safety concerns and limited its therapeutic potential.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 3.2 | 0.3 | 9.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 2.1 | 2 | 0.05 |
| Allergies | 5.7 | 2.2 | 1.59 |
| Allergy to milk products | 1.5 | 1.2 | 0.25 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 4.3 | 4.2 | 0.02 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.8 | 0.7 | 3 |
| Ankylosing spondylitis | 3.3 | 0.9 | 2.67 |
| Anorexia Nervosa | 0.6 | 1.7 | -1.83 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 4.4 | 2.6 | 0.69 |
| Atherosclerosis | 1.5 | 1.6 | -0.07 |
| Atrial fibrillation | 1.9 | 1.2 | 0.58 |
| Autism | 5.6 | 6.3 | -0.13 |
| Autoimmune Disease | 0.9 | 1 | -0.11 |
| Barrett esophagus cancer | 0.6 | 0.6 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 1.4 | 1.1 | 0.27 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.9 | 2.2 | -1.44 |
| Carcinoma | 3.1 | 1.9 | 0.63 |
| Celiac Disease | 1.2 | 3 | -1.5 |
| Cerebral Palsy | 1.3 | 1 | 0.3 |
| Chronic Fatigue Syndrome | 3 | 3.4 | -0.13 |
| Chronic Kidney Disease | 3.6 | 1.3 | 1.77 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.4 | -0.56 |
| Chronic Urticaria (Hives) | 1.4 | 0.4 | 2.5 |
| Coagulation / Micro clot triggering bacteria | 0.9 | 0.7 | 0.29 |
| Cognitive Function | 2.1 | 1.3 | 0.62 |
| Colorectal Cancer | 3.8 | 1.9 | 1 |
| Constipation | 1.2 | 0.7 | 0.71 |
| Coronary artery disease | 1.2 | 1.5 | -0.25 |
| COVID-19 | 7.9 | 7.8 | 0.01 |
| Crohn's Disease | 4.7 | 4 | 0.18 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.9 | 1.8 | -1 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 1.2 | 0.8 | 0.5 |
| Denture Wearers Oral Shifts | 0.7 | 0.7 | |
| Depression | 7.4 | 6.5 | 0.14 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 1.4 | 1 | 0.4 |
| Endometriosis | 2.2 | 1.7 | 0.29 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.4 | 1.3 | 0.85 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.2 | 0.8 | 1.75 |
| Functional constipation / chronic idiopathic constipation | 3.5 | 2.1 | 0.67 |
| gallstone disease (gsd) | 2.1 | 1.3 | 0.62 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 1 | -0.43 |
| Generalized anxiety disorder | 2.1 | 1.6 | 0.31 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 1.6 | 0.4 | 3 |
| Graves' disease | 1.2 | 2.4 | -1 |
| Gulf War Syndrome | 0.3 | 1.2 | -3 |
| Halitosis | 1 | 1 | |
| Hashimoto's thyroiditis | 2.6 | 1.1 | 1.36 |
| Heart Failure | 2.5 | 1.2 | 1.08 |
| hemorrhagic stroke | 0.9 | 0.9 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.1 | 0.3 | 2.67 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.4 | 1 |
| hyperglycemia | 2.1 | 1.3 | 0.62 |
| Hyperlipidemia (High Blood Fats) | 0.8 | 0.3 | 1.67 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.1 | 4.3 | -0.39 |
| Hypothyroidism | 0.2 | 0.7 | -2.5 |
| Hypoxia | 2.5 | 0.3 | 7.33 |
| IgA nephropathy (IgAN) | 0.9 | 3.4 | -2.78 |
| Inflammatory Bowel Disease | 5.4 | 6 | -0.11 |
| Insomnia | 1.3 | 2.2 | -0.69 |
| Intelligence | 0.9 | 0.9 | |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 6.1 | 3.5 | 0.74 |
| ischemic stroke | 1.9 | 1.4 | 0.36 |
| Liver Cirrhosis | 5.5 | 4 | 0.38 |
| Long COVID | 4.4 | 6.4 | -0.45 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.3 | 1.1 | 0.18 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.7 | 0.3 | 1.33 |
| ME/CFS with IBS | 0.2 | 1.9 | -8.5 |
| ME/CFS without IBS | 0.8 | 1.8 | -1.25 |
| Menopause | 1.8 | 0.7 | 1.57 |
| Metabolic Syndrome | 5.6 | 5.7 | -0.02 |
| Mood Disorders | 7.5 | 5 | 0.5 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.1 | 4 |
| Multiple Sclerosis | 4.5 | 2.5 | 0.8 |
| Multiple system atrophy (MSA) | 1.2 | 0.4 | 2 |
| myasthenia gravis | 0.6 | 0.7 | -0.17 |
| neuropathic pain | 0.3 | 3 | -9 |
| Neuropathy (all types) | 0.6 | 1.8 | -2 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.6 | 4.3 | 0.07 |
| NonCeliac Gluten Sensitivity | 1.7 | 0.6 | 1.83 |
| Obesity | 8.8 | 5.9 | 0.49 |
| obsessive-compulsive disorder | 3.7 | 2 | 0.85 |
| Osteoarthritis | 1.5 | 0.8 | 0.88 |
| Osteoporosis | 2.2 | 1.4 | 0.57 |
| pancreatic cancer | 0.4 | 0.4 | |
| Parkinson's Disease | 6.2 | 3.7 | 0.68 |
| Polycystic ovary syndrome | 3 | 2 | 0.5 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 0.9 | 0.8 | 0.13 |
| Primary sclerosing cholangitis | 1.7 | 1 | 0.7 |
| Psoriasis | 2.6 | 1.2 | 1.17 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.4 | 3.2 | 0.69 |
| Rosacea | 0.3 | 0.7 | -1.33 |
| Schizophrenia | 4.9 | 2.2 | 1.23 |
| scoliosis | 0.3 | 0.4 | -0.33 |
| Sjögren syndrome | 1.9 | 1.9 | 0 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.6 | 1.33 |
| Stress / posttraumatic stress disorder | 2.7 | 2.1 | 0.29 |
| Systemic Lupus Erythematosus | 2.4 | 1.5 | 0.6 |
| Tic Disorder | 0.3 | 1.2 | -3 |
| Tourette syndrome | 0.8 | 0.3 | 1.67 |
| Type 1 Diabetes | 2.5 | 3.1 | -0.24 |
| Type 2 Diabetes | 5.4 | 4.9 | 0.1 |
| Ulcerative colitis | 3.3 | 4.4 | -0.33 |
| Unhealthy Ageing | 2.4 | 1.3 | 0.85 |
| Vitiligo | 0.9 | 0.7 | 0.29 |
